The portfolio maintains a cost advantage over competitors, priced within the second-lowest fee quintile among peers.
Tema Oncology ETF CANC ETF Analysis
Morningstar’s Analysis CANC
Will CANC outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar